“An Unrelenting Disaster Zone”: Merck’s Alzheimer’s Drug Fails in Phase III Post author:Sam Post published:February 13, 2018 Post category:BioPharma Alzheimer’s drug development took another hit. Source: BioSpace You Might Also Like TG Therapeutics Announces Updated Results From the Ongoing Phase II Study of Ublituximab in Patie… February 1, 2018 Bristol-Myers Forks Over $40M Upfront for Another One of Ono Pharma's Cancer Prospects December 13, 2017 Can This Region Become the Country???s Next Big Biotech Hub for Jobs? July 19, 2017
TG Therapeutics Announces Updated Results From the Ongoing Phase II Study of Ublituximab in Patie… February 1, 2018
Bristol-Myers Forks Over $40M Upfront for Another One of Ono Pharma's Cancer Prospects December 13, 2017
